Format

Send to

Choose Destination
Adv Exp Med Biol. 2018;1083:145-156. doi: 10.1007/5584_2017_127.

Intravenous Infusion of Human Adipose Tissue-Derived Mesenchymal Stem Cells to Treat Type 1 Diabetic Mellitus in Mice: An Evaluation of Grafted Cell Doses.

Author information

1
Stem Cell Institute, University of Science, VNUHCM, Ho Chi Minh city, Vietnam.
2
Laboratory of Stem Cell Research and Application, University of Science, VNUHCM, Ho Chi Minh city, Vietnam.
3
Medical Genetics Institute, Ho Chi Minh city, Vietnam.
4
Stem Cell Institute, University of Science, VNUHCM, Ho Chi Minh city, Vietnam. pvphuc@hcmuns.edu.vn.
5
Laboratory of Stem Cell Research and Application, University of Science, VNUHCM, Ho Chi Minh city, Vietnam. pvphuc@hcmuns.edu.vn.

Abstract

Mesenchymal stem cell (MSC) transplantation is a novel treatment for diabetes mellitus, especially type 1 diabetes. Many recent publications have demonstrated the efficacy of MSC transplantation on reducing blood glucose and increasing insulin production in both preclinical and clinical trials. However, the investigation of grafted cell doses has been lacking. Therefore, this study aimed to evaluate the different doses of MSCs on treatment of type 1 diabetes in mouse models. MSCs were isolated and expanded from human adipose tissue. Streptozotocin (STZ)-induced diabetic mice were divided into two groups that were intravenously transfused with two different doses of human MSCs: 106 or 2.106 cells/mouse. After transplantation, both grafted and placebo mice were monitored weekly for their blood glucose levels, glucose and insulin tolerance, pancreatic structural changes, and insulin production for 56 days after transplantation. The results showed that the higher dose of MSCs (2.106 cells/mouse) remarkably reduced death rate. The death rates were 50%, 66%, and 0% in placebo group, low-dose (1.106 MSCs) group, and high-dose (2.106 MSCs) group, respectively, after 56 days of treatment. Moreover, blood glucose levels were lower for the high-dose group compared to other groups. Glucose and insulin tolerance, as well as insulin production, were significantly improved in mice transplanted with 2.106 cells. The histochemical analyses also support these results. Thus, a higher (e.g., 2.106) dose of MSCs may be an effective dose for treatment of type 1 diabetes mellitus.

KEYWORDS:

Adipose-derived stem cells; Cell dose; Diabetes mellitus; Islet regeneration; Mesenchymal stem cells; Stem cells

PMID:
29423674
DOI:
10.1007/5584_2017_127

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center